Clinical trials: HFpEF
Heart Failure
Chronotropic Incompetence in Patients With HFpEF
The purpose of this study is to determine the mechanisms of chronotropic incompetence (inability to increase heart rate with exercise) in patients with heart failure and preserved ejection fraction (HFpEF).
- Trial name
- NCT02524145
- Testing
- Static Handgrip, Dexmedetomidine, Glycopyrrolate
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Heart Failure With Preserved Ejection Fraction, Low Triiodothyronine Syndrome
Developing Oral LT3 Therapy for Heart Failure - HFpEF
Investigation of the safety, feasibility, and preliminary efficacy of thyroid hormone therapy with Liothyronine (LT3) in individuals with heart failure with preserved ejection fraction (HFpEF) and low triiodothyronine (T3)…
- Trial name
- DOT3HF-HFpEF (NCT04111536)
- Testing
- liothyronine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Pennsylvania
Heart Failure, Congestive Heart Failure
Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction
The main objective is to test the effect of prolonged therapy (24 weeks) with isosorbide dinitrate ± hydralazine on arterial wave reflections (primary endpoint).
- Trial name
- NCT01516346
- Testing
- Isosorbide Dinitrate, Isosorbide Dinitrate + Hydralazine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Corporal Michael J. Crescenz VA Medical Center
Heart Failure, Diastolic
Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction
Heart Failure with preserved Ejection Fraction (HFPEF) accounts for 40-50% of all heart failure patients with a frequency of hospital admissions for acute decompensation and short and long term mortality similar to patients with…
- Trial name
- ROPA-DOP (NCT01901809)
- Testing
- Furosemide, Dopamine
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Johns Hopkins University
Heart Failure With Preserved Ejection Fraction (HFpEF)
An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.
This study evaluated the safety and tolerability of LCZ696 treatment in Japanese heart failure patients (NYHA Class II-IV) with preserved ejection fraction after CLCZ696D2301 (PARAGON-HF).
- Trial name
- NCT03909295
- Testing
- LCZ696
- Where
- 17 sites in Japan
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure With Preserved Ejection Fraction (HFpEF)
Study of Verinurad in Heart Failure With Preserved Ejection Fraction
International, Multicenter, Double-Blind, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad combined with Allopurinol in Heart Failure with Preserved Ejection Fraction
- Trial name
- AMETHYST (NCT04327024)
- Testing
- Verinurad, Allopurinol
- Where
- 58 sites in United States, Argentina and 10 more
- Volunteers
- 159 people
- Sponsor
- AstraZeneca
Heart Failure With Normal Ejection Fraction
Interleukin-1 Blockade in HF With Preserved EF
Heart Failure with Preserved Ejection Fraction (HFpEF) is a common form of heart failure Standard treatment for heart failure, show less than ideal results in HFpEF Evidence of systemic inflammation is common in all forms of…
- Trial name
- D-HART2 (NCT02173548)
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Virginia Commonwealth University
Congestive Heart Failure, Heart Failure, Diastolic
Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFpEF Patients Treated With Allogeneic CDCs
Perform a randomized, double blind, placebo-controlled Phase 2a feasibility study to determine whether treatment of HFpEF patients with intracoronary allogeneic CDCs affects clinical functional status (QOL scores), exercise…
- Trial name
- RegressHFpEF (NCT02941705)
- Testing
- Allogeneic Derived Cells
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Cedars-Sinai Medical Center
Heart Failure With Preserved Ejection Fraction
Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
This is a randomised, double-blind, placebo-controlled, multi-center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with…
- Trial name
- ENDEAVOR (NCT04986202)
- Testing
- AZD4831
- Where
- 171 sites in United States, Australia and 16 more
- Volunteers
- 711 people
- Sponsor
- AstraZeneca
Heart Failure
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
This is a study in adults with chronic heart failure. People with chronic heart failure may need to be hospitalised for their condition. Some people with chronic heart failure may eventually die from their condition.
- Trial name
- NCT03057951
- Testing
- Empagliflozin
- Where
- 619 sites in United States, Argentina and 21 more
- Volunteers
- 5,988 people
- Sponsor
- Boehringer Ingelheim
Heart Failure
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard diuretic and comorbidity treatment for heart…
- Trial name
- NCT01951638
- Testing
- Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg)
- Where
- 158 sites in United States, Australia and 23 more
- Volunteers
- 477 people
- Sponsor
- Bayer
Heart Failure
Inorganic Nitrite to Amplify the Benefits and Tolerability of Exercise Training in Heart Failure With Preserved Ejection Fraction (HFpEF) (INABLE-Training)
Participants with heart failure with preserved ejection fraction will undergo 12 weeks of cardiac rehabilitation for exercise training (ET) and be randomized to either sodium nitrite or placebo through the training period.
- Trial name
- INABLE (NCT02713126)
- Testing
- Sodium Nitrite, Accelerometer, Cardiac Exercise Training
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Barry Borlaug
Heart Failure
Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF)
This trial seeks to assess if potassium nitrate (KNO3) therapy improves exercise capacity and oxygen uptake in heart failure patients with preserved ejection fraction (HFpEF).
- Trial name
- NCT02840799
- Testing
- Potassium Nitrate (KNO3), Potassium Chloride (KCl)
- Where
- 3 sites in United States
- Volunteers
- 84 people
- Sponsor
- University of Pennsylvania
Heart Failure With a Preserved Ejection Fraction, Heart Failure, Diastolic
Efficacy Study of Pacemakers to Treat Slow Heart Rate in Patients With Heart Failure
Determine the impact of restoring normal heart rate response during exercise and daily activity in patients with heart failure and a preserved ejection fraction (HFpEF) and chronotropic incompetence (CI).
- Conditions
- Heart Failure With a Preserved Ejection Fraction, Heart Failure, Diastolic, Chronotropic Incompetence
- Trial name
- RAPID-HF (NCT02145351)
- Testing
- Rate adaptive atrial pacing using a dual-chamber pacemaker, Pacemaker system will be implanted but set to Pacing Off.
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Mayo Clinic